NEW YORK (GenomeWeb) – Precision medicine platform vendor 2bPrecise has signed an agreement to provide its cloud-based platform for the capture and dissemination of genomic information from Avera Health's GeneFolio medication test.
2bPrecise's platform is designed to help clinicians more easily incorporate a patient's genomic information into their routine clinical workflows. It uses clinical-genomic ontologies and data harmonization methods to combine genomic, clinical, and lifestyle information, and provides access to this information in a machine-readable and structured format that supports statistical analysis and pattern detection.
GeneFolio is a blood-based test that analyzes a patient's genetic makeup in order to predict how they will respond to specific medications in order to determine optimal dosing, increase treatment success, and limit side effects. Avera is a South Dakota-based integrated health system and a member-owner of the for-profit healthcare incubator the Innovation Institute.
Under the terms of the agreement, 2bPrecise's platform will be used to structure and deliver GeneFolio results to physicians within the Avera system and across the Innovation Institute's other health systems, which represent 125 hospitals in 20 states.
Other member-owners of the Innovation Institute include Bon Secours Health System, Children's Hospital of Orange County, Franciscan Missionaries of Our Lady Health System, Mercy Health, and Providence St. Joseph Health.
Additional terms of the deal were not disclosed.
In mid-2017, Mayo Clinic licensed 2bPrecise's genomics and precision medicine solution as part of a partnership to develop and test care protocols for genomics. The year before, the company signed deals to provide its technology to Holston Medical Group and the National Institutes of Health.